Simulations Plus to Present at LD Micro 11th Annual Main Event Investor Conference on December 4, 2018
November 20 2018 - 8:30AM
Business Wire
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of
software for pharmaceutical discovery and development, today
announced that Shawn O’Connor, chief executive officer, and John
Kneisel, chief financial officer, will present at the 11th Annual
LD Micro Main Event investor conference at 9 a.m. PT on Tuesday,
December 4, 2018, at the Luxe Sunset Boulevard Hotel in Los
Angeles, California. The conference will be held December 4-6,
2018.
In addition, management will be available during the day on
Tuesday and Wednesday, December 4 and 5, for one-on-one meetings.
For more information about the conference or to schedule a
one-on-one meeting with management, please contact Hayden IR at
slp@haydenir.com. Following the presentation, the slides will be
available via the Resource Center at the Simulations Plus website
(www.simulations-plus.com).
About LD Micro
LD Micro was founded in 2006 with the sole purpose of being an
independent resource in the microcap space. What started out as a
newsletter highlighting unique companies has transformed into
several influential events annually (Invitational, Summit and Main
Event). In 2015, LD Micro launched ldmicro.com as a portal to
provide exclusive intraday information on the entire sector,
including the first pure micro-cap index (LDMi), which covers
stocks in North America with market capitalizations between $50
million to $300 million.
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of drug discovery
and development software as well as a leading provider of both
preclinical and clinical pharmacometric consulting services for
regulatory submissions and quantitative systems pharmacology models
for drug-induced liver injury and nonalcoholic fatty liver disease.
The company is a global leader focused on improving the ways
scientists use knowledge and data to predict the properties and
outcomes of pharmaceutical, biotechnology, and chemical agents. Our
software is licensed to and used in the conduct of drug research by
major pharmaceutical, biotechnology, chemical, and consumer goods
companies and regulatory agencies worldwide. Our innovations in
integrating new and existing science in medicinal chemistry,
computational chemistry, pharmaceutical science, biology, and
physiology into our software have made us the leading software
provider for physiologically based pharmacokinetic modeling and
simulation. For more information, visit our website at
www.simulations-plus.com.
Follow us on Twitter | LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181120005210/en/
Simulations Plus Investor
RelationsMs. Renee Bouche,
661-723-7723renee@simulations-plus.comorHayden IRMr. Cameron Donahue,
651-653-1854cameron@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Apr 2023 to Apr 2024